Klotz, U. (2007). “The role of pharmacogenetics in the metabolism of antiepileptic drugs: pharmacokinetic and therapeutic implications.”. Clin Pharmacokinet46 (4): 271–9. doi:10.2165/00003088-200746040-00001. PMID17375979.
Roses AD (June 2000). “Pharmacogenetics and the practice of medicine”. Nature405 (6788): 857–65. doi:10.1038/35015728. PMID10866212.
“Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies”. JAMA279 (15): 1200–5. (April 1998). doi:10.1001/jama.279.15.1200. PMID9555760.
“Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy”. JAMA302 (8): 849–57. (August 2009). doi:10.1001/jama.2009.1232. PMID19706858.
“DPD-based adaptive dosing of 5-FU in patients with head and neck cancer: impact on treatment efficacy and toxicity”. Cancer Chemother. Pharmacol.67 (1): 49–56. (January 2011). doi:10.1007/s00280-010-1282-4. PMID20204365.
nih.gov
pubmed.ncbi.nlm.nih.gov
Klotz, U. (2007). “The role of pharmacogenetics in the metabolism of antiepileptic drugs: pharmacokinetic and therapeutic implications.”. Clin Pharmacokinet46 (4): 271–9. doi:10.2165/00003088-200746040-00001. PMID17375979.
Roses AD (June 2000). “Pharmacogenetics and the practice of medicine”. Nature405 (6788): 857–65. doi:10.1038/35015728. PMID10866212.
“Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies”. JAMA279 (15): 1200–5. (April 1998). doi:10.1001/jama.279.15.1200. PMID9555760.
“Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy”. JAMA302 (8): 849–57. (August 2009). doi:10.1001/jama.2009.1232. PMID19706858.
“DPD-based adaptive dosing of 5-FU in patients with head and neck cancer: impact on treatment efficacy and toxicity”. Cancer Chemother. Pharmacol.67 (1): 49–56. (January 2011). doi:10.1007/s00280-010-1282-4. PMID20204365.